VHL and clear cell renal carcinoma: These inhibitors from the same substance class have been or are currently under investigation in phase II clinical trials targeting clear cell renal cell carcinoma (PT2385: NCT03108066), recurrent glioblastoma (PT2985: NCT03216499), and VHL-associated RCC (PT2977: NCT03401788).